These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 11386410)

  • 41. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas].
    Mizumatsu S; Matsumoto K; Maeda Y; Tamiya T; Furuta T; Ohmoto T
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2055-60. PubMed ID: 9838907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer.
    Jeremic B; Jevremovic S; Mijatovic L; Milisavljevic S
    Cancer; 1993 Jun; 71(11):3732-6. PubMed ID: 8387885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study.
    Jeremic B; Grujicic D; Jevremovic S; Stanisavljevic B; Milojevic L; Djuric L; Mijatovic L
    J Clin Oncol; 1992 Jul; 10(7):1074-7. PubMed ID: 1318951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
    Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ
    J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study.
    Jeremic B; Shibamoto Y; Acimovic L; Matovic Z; Milicic B; Milisavljevic S; Nikolic N
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1061-6. PubMed ID: 9539560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1997 Mar; 15(3):893-900. PubMed ID: 9060525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study.
    Viñolas N; Gil M; Verger E; Villá S; Pujol T; Ceral L; García M; Graus F
    Anticancer Drugs; 2002 Feb; 13(2):163-7. PubMed ID: 11901309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
    Jeremić B; Milicić B; Acimović L; Milisavljević S
    J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
    Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.
    Anders K; Grabenbauer GG; Schuchardt U; Fahlbusch R; Fietkau R; Sauer R; Krauseneck P
    J Neurooncol; 2000 May; 48(1):63-73. PubMed ID: 11026699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
    Jeremić B; Milićić B
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):426-32. PubMed ID: 17306936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
    Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
    Fountzilas G; Karkavelas G; Kalogera-Fountzila A; Karina M; Ignatiadis M; Koukoulis G; Plataniotis G; Misailidou D; Bobos M; Pectasides D; Razis E; Karavelis A; Selviaridis P
    Anticancer Res; 2006; 26(6C):4675-86. PubMed ID: 17214326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response and progression in recurrent malignant glioma.
    Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
    Neuro Oncol; 1999 Oct; 1(4):282-8. PubMed ID: 11550320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma.
    Peterson K; Harsh G; Fisher PG; Adler J; Le Q
    J Neurooncol; 2001 May; 53(1):27-32. PubMed ID: 11678427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases.
    Shibamoto Y; Yamashita J; Takahashi M; Yamasaki T; Kikuchi H; Abe M
    Radiother Oncol; 1990 May; 18(1):9-17. PubMed ID: 2163064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience.
    Díaz R; Jordá MV; Reynés G; Aparicio J; Segura A; Amador R; Calderero V; Beltrán A
    Anticancer Drugs; 2005 Mar; 16(3):323-9. PubMed ID: 15711185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.